Vanguard Group Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 0.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,933,549 shares of the company's stock after selling 39,381 shares during the quarter. Vanguard Group Inc. owned approximately 9.03% of 10x Genomics worth $157,006,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in TXG. LPL Financial LLC raised its stake in 10x Genomics by 26.2% in the 4th quarter. LPL Financial LLC now owns 33,771 shares of the company's stock valued at $485,000 after purchasing an additional 7,014 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of 10x Genomics during the fourth quarter worth $277,000. Quantbot Technologies LP acquired a new stake in shares of 10x Genomics in the fourth quarter valued at about $1,026,000. Counterpoint Mutual Funds LLC acquired a new stake in shares of 10x Genomics in the fourth quarter valued at about $742,000. Finally, Signaturefd LLC lifted its stake in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after buying an additional 1,452 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.
10x Genomics Price Performance
Shares of TXG traded up $0.31 during midday trading on Friday, reaching $8.01. 3,349,046 shares of the stock were exchanged, compared to its average volume of 2,165,375. 10x Genomics, Inc. has a twelve month low of $6.78 and a twelve month high of $36.15. The company has a market capitalization of $979.64 million, a price-to-earnings ratio of -5.27 and a beta of 2.01. The business's 50-day moving average price is $10.44 and its 200 day moving average price is $13.96.
10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, equities research analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.
Insider Transactions at 10x Genomics
In related news, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Alan Mateo purchased 40,000 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was purchased at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the acquisition, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 10.03% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. Citigroup decreased their target price on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Canaccord Genuity Group lowered their price objective on 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Leerink Partners cut 10x Genomics from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $25.00 to $12.00 in a report on Thursday, February 13th. Stifel Nicolaus reduced their price target on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research report on Tuesday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $19.79.
Read Our Latest Research Report on TXG
About 10x Genomics
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Stories
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
